Modality
Vaccine
MOA
ALKi
Target
FGFR
Pathway
Innate Imm
T2DPancreatic CaNB
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
~Dec 2019
→ ~Mar 2021
Phase 2
~Jun 2021
→ ~Sep 2022
Phase 3
~Dec 2022
→ ~Mar 2024
NDA/BLA
Jun 2024
→ Oct 2026
NDA/BLACurrent
NCT04506094
348 pts·NB
2024-06→2026-10·Active
348 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-10-116mo awayPh3 Readout· NB
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph3 Readout
2026-10-11 · 6mo away
NB
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04506094 | NDA/BLA | NB | Active | 348 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA |